-- 周二,受媒体报道美国和伊朗可能重启和平谈判的消息提振,美国股指期货走高。投资者正等待华尔街几家大型银行的最新财务业绩以及批发价格数据。 标普500指数上涨0.2%,道琼斯工业平均指数小幅上涨0.1%,纳斯达克指数在盘前交易中上涨0.4%。各大股指在前一交易日均收高,其中纳斯达克指数连续第九个交易日上涨。 彭博新闻周二援引知情人士的话报道称,美国和伊朗正在考虑在目前为期两周的停火协议下周到期前举行新一轮谈判。 据报道,美国总统唐纳德·特朗普周一表示,“合适的人”已经与华盛顿方面接触,“他们希望达成协议”。此前,美伊代表团周末在巴基斯坦举行的谈判未能达成协议。 据美国消费者新闻与商业频道(CNBC)报道,美国副总统约翰·万斯在接受福克斯新闻采访时表示,伊朗是否继续推进与美国的和平谈判,取决于伊朗方面。万斯表示:“无论我们是否继续对话,最终是否达成协议,我认为主动权都在伊朗手中,因为我们已经做出了很多让步。” 周一,美国海军开始封锁霍尔木兹海峡的伊朗港口。 西德克萨斯中质原油(WTI)在开盘前下跌2.6%,至每桶96.53美元;布伦特原油下跌1.2%,至每桶91.88美元。 国际能源署(IEA)周二表示,由于中东战争“颠覆”了其全球前景,预计今年石油需求将下降8万桶/日。IEA表示:“随着供应短缺和价格持续走高,需求下降的趋势将会蔓延。” 周一,石油输出国组织(欧佩克)下调了第二季度石油需求预期,原因是中东冲突,但由于预期下半年石油需求将反弹,因此维持了全年预期。 摩根大通(JPM)、富国银行(WFC)和花旗集团(C)等银行业巨头将于盘前公布最新季度财报,强生(JNJ)、贝莱德(BLK)和艾伯森(ACI)也将公布财报。 高盛(GS)周一公布的第一季度业绩超出市场预期,首席执行官大卫·所罗门表示,旷日持久的中东冲突可能对通胀构成上行风险。美国银行(BAC)和摩根士丹利(MS)将于周三公布业绩。 上月生产者价格指数(衡量批发价格的指标)预计将于美国东部时间上午8:30发布。上周公布的政府数据显示,受中东冲突导致能源价格大幅上涨的影响,3月份消费者通胀率飙升至近四年来的最高月度水平。 美国国债收益率在盘前交易中走低,两年期国债收益率下跌1.9个基点至3.76%,十年期国债收益率下跌1.6个基点至4.28%。 美联储理事迈克尔·巴尔将于下午12:45发表讲话,而芝加哥联储主席奥斯坦·古尔斯比将于下午12:15发表讲话。 甲骨文公司(ORCL)股价在盘前交易中上涨4.2%,此前该公司股价在前一交易日收盘上涨13%,原因是该公司宣布对其公用事业软件套件进行了人工智能方面的更新。Avanos Medical(AVNS)股价飙升68%,此前该公司同意被美国工业伙伴公司(American Industrial Partners)的关联公司以12.7亿美元的价格收购。 盘前黄金价格上涨 0.8% 至每盎司 4,804 美元,而比特币价格上涨 2% 至 74,609 美元。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.